Avelumab and Merkel Cell Carcinoma: A Comprehensive Review of Causation Claims

From General Health to Occupational Hazard

For decades, public health communication has centered on general wellness principles, emphasizing lifestyle factors such as diet, exercise, and routine screenings to mitigate disease risk. This broad framework has served as the foundation for understanding how environmental and behavioral exposures influence long-term health outcomes. Within this legacy, the role of pharmaceutical agents has been primarily discussed in terms of therapeutic benefit, with less attention given to potential unintended consequences of sustained exposure in occupational settings. As we pivot to a more specialized domain, the focus narrows to a specific immunotherapeutic agent: Avelumab. This monoclonal antibody, approved for certain oncological indications, represents a class of drugs that modulate immune system activity. In the context of mass production, workers involved in the synthesis, formulation, or handling of Avelumab may face unique exposure scenarios. The transition from general health literacy to occupational hazard assessment requires careful consideration of how chronic, low-level contact with such bioactive compounds could influence cellular regulation.

Bridging to Occupational Risk Assessment

The bridge concept here is the shift from population-level health advice to workplace-specific risk evaluation. While the general public may encounter Avelumab only as a prescribed therapy, production personnel experience repeated dermal or inhalational exposure during manufacturing processes. This occupational dimension demands a distinct analytical lens—one that moves beyond therapeutic efficacy to examine potential long-term consequences of unintended exposure, including any association with malignancies such as Merkel cell carcinoma.

Avelumab: Mechanism and Approved Use

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Evaluating the Causation Claim: Avelumab as Treatment, Not Cause

The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but rather of therapeutic action. Avelumab is used to treat MCC, not to cause it. The drug's mechanism involves blocking PD-L1, thereby reactivating the immune system to attack cancer cells. However, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Such irAEs are distinct from the primary disease being treated.

Risk Considerations and Adequacy of Warnings

Regarding risk considerations, the adequacy of warnings about avelumab and MCC must be evaluated in the context of its approved use. The drug's prescribing information includes warnings about immune-mediated adverse reactions, but the primary risk for patients is not that avelumab causes MCC but rather that the disease may be refractory to treatment. For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have explored the use of combined ipilimumab and nivolumab in avelumab-refractory MCC. In a multicenter study, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab approved for advanced MCC, but approximately 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Timeline and Causation Considerations for Affected Patients

Causation-related considerations for affected patients focus on the timeline between exposure to avelumab and documented harm. Since avelumab is a treatment for MCC, the timeline of harm is typically related to disease progression or irAEs. For example, in the case of sarcoidosis reactivation, hypercalcaemia occurred during treatment with avelumab and was managed without discontinuing therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). In avelumab-refractory patients, progression may occur after initial response or as primary resistance, and the timeline varies. The JAVELIN Merkel 200 trial demonstrated responses in approximately one-third of patients, indicating that a majority may not respond or may progress over time (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Summary of Evidence

In summary, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Instead, avelumab is an established treatment for MCC, with documented efficacy and a known safety profile that includes immune-related adverse events. The primary risk for patients is disease progression or lack of response, and for avelumab-refractory cases, alternative therapies such as combined ipilimumab and nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/). Adequacy of warnings should reflect the drug's therapeutic role and the potential for irAEs, rather than a causation of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It works by blocking PD-L1 to reactivate the immune system against cancer cells. The evidence does not support a causal link between avelumab and the development of MCC.

What are the risks of avelumab therapy?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). The primary risk for patients is disease progression or lack of response, with about 50% of advanced MCC patients progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.